Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Marathon Digital Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Marathon Digital Holdings Inc trades at $12 (market cap $4.59B). The key difference: ACADIA Pharmaceuticals Inc. and Marathon Digital Holdings Inc are close in size by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | MARA | |
|---|---|---|
Market Cap | $4.49B | $4.59B |
Sector | Health | Technology |
52-Week High | $28.06 | $22.84 |
52-Week Low | $20.06 | $6.73 |
Enterprise Value | $3.69B | $6.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
MARA Holdings trades at $12.95, up 4.44% today, but faces significant fundamental challenges with a net income margin of -234.83% and three consecutive quarterly earnings misses. The technical picture remains bearish with key resistance at $13-$14, while analyst sentiment is mixed with a 50% buy rating but a consensus price target of $16.60. Recent developments include the shipment of a hybrid energy storage prototype system from TAE Power Solutions (PRNewsWire, June 30, 2026) and ongoing pivot toward AI infrastructure.
Despite the bullish analyst consensus and potential from AI infrastructure expansion, MARA faces substantial execution risks amid persistent losses and negative cash flow from operations. The stock's valuation appears attractive on P/E (3.37) and EV/EBITDA (3.31) metrics, but profitability concerns and Bitcoin market volatility create significant downside risk for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
